HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human)

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
HAEGARDA C1 Esterase Inhibitor Subcutaneous (Human)
Generic name
HUMAN C1-ESTERASE INHIBITOR
Manufacturer
CSL Behring GmbH
Product type
PLASMA DERIVATIVE
SPL set ID
e270ad38-adc4-4ed5-88e3-943b93d20a57
SPL ID
c53fd34d-f366-4ee5-bbea-88201bf6b7c8
Version
8
Effective date
2022-02-04
Source export date
2026-11-13
Source partition
8
Source file
https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 16:55:24

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS The physician should discuss the risks and benefits of this product with the patient before prescribing or administering it to the patient [see Patient Counseling Information (17) ]. Initiate individualized treatment in case of an acute HAE attack. Severe hypersensitivity reactions may occur. In case of severe hypersensitivity, discontinue HAEGARDA administration and institute appropriate treatment. Epinephrine should be immediately available for treatment of severe hypersensitivity reaction. ( 5.1 ) At the recommended subcutaneous (S.C.) dose, a causal relationship between thromboembolic events (TEEs) and the use of HAEGARDA has not been established. However, thrombosis has occurred in treatment attempts with high doses of C1-INH intravenous (I.V.) for prevention or therapy of capillary leak syndrome before, during or after cardiac surgery (unapproved indication and dose). ( 5.2 ) Because HAEGARDA is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.3 ) 5.1 Hypersensitivity Severe hypersensitivity reactions may occur. The signs and symptoms of hypersensitivity reactions may include hives (local and generalized), tightness of the chest, difficulty breathing, wheezing, hypotension, and/or anaphylaxis during or after injection of HAEGARDA. In case of severe hypersensitivity, discontinue HAEGARDA administration and institute appropriate treatment. Epinephrine should be immediately available for treatment of severe hypersensitivity reaction [see Patient Counseling Information (17) ]. 5.2 Thromboembolic Events At the recommended subcutaneous dose, a causal relationship between thromboembolic events (TEEs) and the use of HAEGARDA has not been established [see Patient Counseling Information (17) ] . Thrombosis has occurred in treatment attempts with high doses of C1-INH intravenous (I.V.) for prevention or therapy of capillary leak syndrome before, during or after cardiac surgery (unapproved indication and dose). 5.3 Transmissible Infectious Agents Because HAEGARDA is made from human blood, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by processes demonstrated to inactivate and/or remove certain viruses during manufacturing [see Description (11) and Patient Counseling Information (17) ] . Despite these measures, such products may still contain human pathogenic agents, including those not yet known or identified. Thus, the risk of transmission of infectious agents cannot be totally eliminated. All infections thought by a physician possibly to have been transmitted by HAEGARDA should be reported by lot number, by the physician or other healthcare provider, to the CSL Behring Pharmacovigilance Department at 1-866-915-6958.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS Adverse reactions occurring in more than 4% of subjects treated with HAEGARDA were injection site reactions, hypersensitivity, nasopharyngitis and dizziness. Adverse reactions occurring in more than 4% of subjects treated with HAEGARDA were injection site reactions, hypersensitivity, nasopharyngitis and dizziness. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Of the 90 subjects randomized in the double-blind, placebo-controlled, cross-over study (Study 1) [see Clinical Studies (14) ] , 86 subjects received at least one dose of HAEGARDA and 86 subjects received at least one dose of placebo (Table 1). A total of 5081 injections of HAEGARDA and placebo were administered over a range of 3 to 19 weeks (median of 16.6 weeks for HAEGARDA; median of 16.3 weeks for placebo). Eligible patients were also able to participate in a randomized, open-label, active treatment-controlled study (Study 2) for up to 140 weeks (n=120). Table 1. Adverse Reactions in >4% of Subjects Treated with HAEGARDA MedDRA System Organ Class Adverse Reaction HAEGARDA Placebo (N=86) 60 IU/kg (N=43) 40 IU/kg (N=43) Overall Includes subjects who were treated with 40 IU/kg or 60 IU/kg HAEGARDA. (N=86) n (%) n (%) n (%) n (%) N = number of subjects receiving the treatment; n = number of subjects experiencing ≥1 event. General Disorders and Administration Site Conditions Injection Site Reaction Includes: Injection site bruising, coldness, discharge, erythema, hematoma, hemorrhage, induration, edema, pain, pruritus, rash, reaction, scar, swelling, urticaria, warmth. 15 (35) 12 (28) 27 (31) 21 (24) Immune System Disorders Hypersensitivity Includes: hypersensitivity, pruritus, rash, and urticaria. 3 (7) 2 (5) 5 (6) 1 (1) Infections and Infestations Nasopharyngitis 8 (19) 1 (2) 9 (11) 6 (7) Nervous System Disorders Dizziness 0 (0) 4 (9) 4 (5) 1 (1) Of the injection site reactions occurring after treatment with HAEGARDA, 95% were of mild intensity and 83% resolved within 1 day after onset. Overall, safety data from the open-label study (Study 2), consisting of 59 patients who participated in Study 1 and 61 patients who did not participate in Study 1 (n=120), were consistent with the safety data from the randomized, double-blind, placebo-controlled, crossover, routine prophylaxis trial (Study 1).

adverse reactions table

<table width="100%"><caption>Table 1. Adverse Reactions in &gt;4% of Subjects Treated with HAEGARDA</caption><col width="38%" align="left" valign="middle"/><col width="14%" align="left" valign="middle"/><col width="12%" align="center" valign="middle"/><col width="12%" align="center" valign="middle"/><col width="12%" align="center" valign="middle"/><col width="12%" align="center" valign="middle"/><thead><tr><th valign="bottom" styleCode="Lrule Rrule" rowspan="3">MedDRA System Organ Class</th><th valign="bottom" styleCode="Rrule" rowspan="3">Adverse Reaction</th><th valign="bottom" styleCode="Rrule Botrule" colspan="3">HAEGARDA</th><th valign="bottom" styleCode="Rrule Botrule" rowspan="2">Placebo (N=86)</th></tr><tr styleCode="Botrule"><th align="center" valign="bottom" styleCode="Rrule">60 IU/kg (N=43)</th><th align="center" valign="bottom" styleCode="Rrule">40 IU/kg (N=43)</th><th align="center" valign="bottom" styleCode="Rrule"> Overall<footnote>Includes subjects who were treated with 40 IU/kg or 60 IU/kg HAEGARDA.</footnote> (N=86)</th></tr><tr styleCode="Botrule"><th align="center" valign="bottom" styleCode="Rrule">n (%)</th><th align="center" valign="bottom" styleCode="Rrule">n (%)</th><th align="center" valign="bottom" styleCode="Rrule">n (%)</th><th align="center" valign="bottom" styleCode="Rrule">n (%)</th></tr></thead><tfoot><tr><td colspan="6" align="left">N = number of subjects receiving the treatment; n = number of subjects experiencing &#x2265;1 event.</td></tr></tfoot><tbody><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">General Disorders and Administration Site Conditions</content></td><td styleCode="Rrule">Injection Site Reaction<footnote>Includes: Injection site bruising, coldness, discharge, erythema, hematoma, hemorrhage, induration, edema, pain, pruritus, rash, reaction, scar, swelling, urticaria, warmth.</footnote></td><td styleCode="Rrule">15 (35)</td><td styleCode="Rrule">12 (28)</td><td styleCode="Rrule">27 (31)</td><td styleCode="Rrule">21 (24)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Immune System Disorders</content></td><td styleCode="Rrule">Hypersensitivity<footnote>Includes: hypersensitivity, pruritus, rash, and urticaria.</footnote></td><td styleCode="Rrule">3 (7)</td><td styleCode="Rrule">2 (5)</td><td styleCode="Rrule">5 (6)</td><td styleCode="Rrule">1 (1)</td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule"><content styleCode="bold">Infections and Infestations</content></td><td styleCode="Rrule">Nasopharyngitis</td><td styleCode="Rrule">8 (19)</td><td styleCode="Rrule">1 (2)</td><td styleCode="Rrule">9 (11)</td><td styleCode="Rrule">6 (7)</td></tr><tr><td styleCode="Lrule Rrule"><content styleCode="bold">Nervous System Disorders</content></td><td styleCode="Rrule">Dizziness</td><td styleCode="Rrule">0 (0)</td><td styleCode="Rrule">4 (9)</td><td styleCode="Rrule">4 (5)</td><td styleCode="Rrule">1 (1)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.